Brief: Allarity Therapeutics Doses Second Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer
27/06/2025 13:06
June 27 (Reuters) - Allarity Therapeutics Inc ALLR.O: ALLARITY THERAPEUTICS ANNOUNCES DOSING OF SECOND PATIENT IN NEW PHASE 2 TRIAL OF STENOPARIB IN ADVANCED OVARIAN CANCER Source text: ID:nGNXbD7lY9 Further company coverage: ALLR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic